

EnzymaticTherapy®
NATURAL MEDICINES™

July 2, 2003

Mr. Robert Moore
Office of Nutritional Products, Labeling &
Dietary Supplements, HFS 811
Food and Drug Administration
5100 Paint Branch Parkway
College Park, MD 20740

RECEIVED
JUL 14 2003
BY:

RE: Label Claims/Disclaimers

Dear Mr. Moore:

This letter is to notify you that Enzymatic Therapy, Inc. at 825 Challenger Drive, Green Bay, Wisconsin 54311 is a distributor and has included statements provided for by section 403(r)(6) of the Food, Drug, and Cosmetic Act on the labels of the following product. These claims are not necessarily for a product we currently market or plan to market in the immediate future, and may be exploratory in nature.

COMPANY	PRODUCT NAME	DIETARY INGREDIENTS	STATEMENTS
Enzymatic Therapy, Inc.	Vitaline® CoQ10	Vitamin E, Coenzyme Q10	Vitaline CoQ10, the subject of more than 20 scientific studies at prestigious organizations including Harvard Medical School and Veterans Administration Health Care System, has been shown to cross cell membranes and increase mitochondrial levels of CoQ10.* That's critical, since CoQ10 assists in oxygen use and energy production by the body's cells, especially heart muscles cells.* Plus, Vitaline CoQ10 demonstrated ability to cross the blood-brain barrier results in increased brain intercellular levels of CoQ10 to support neurological health.*

I certify that the information contained in this notice is complete and accurate and that Enzymatic Therapy, Inc. has substantiation that the statements are truthful and not misleading.

By: Robert C. Doster
Robert C. Doster
Title: Senior Vice President of Scientific Affairs

Date: 7/2/03

Vitaline CoQ10 36e

979 0162

LET


12247

85033

825 Challenger Drive
Green Bay, WI 54311-8328
Ph: 920-469-1313
Fax: 888-570-6460
www.enzy.com

If you have any questions, please contact Robert Doster, Senior Vice President of Scientific Affairs at (920) 406-3608.

Sincerely,

A handwritten signature in black ink, appearing to read "Michael P. Devereux". The signature is fluid and cursive, with the first name "Michael" being the most prominent.

Michael P. Devereux
Chief Financial Officer